Abstract
It is widely accepted that blood coagulation in vivo is initiated during normal hemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor, is exposed to the blood as a consequence of vascular injury. In addition to its essential role in hemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons, the tissue factor:factor VIIa complex has been the subject of intense research focus. Many experimental studies have demonstrated that inhibition of tissue factor:factor VIIa procoagulant activity are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared to other “more classical” antithrombotic interventions. Alternative approaches may be represented by transfecting the arterial wall with natural inhibitors of tissue factor:factor VIIa complex, such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without incurring in potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in patients.
Keywords: tissue factor coagulation pathway, hemostasis, tissue factor, factor VIIa procoagulant, antithrombotic interventions
Current Vascular Pharmacology
Title: Inhibition of the Tissue Factor Coagulation Pathway
Volume: 2 Issue: 4
Author(s): Paolo Golino, Lavinia Forte and Salvatore De Rosa
Affiliation:
Keywords: tissue factor coagulation pathway, hemostasis, tissue factor, factor VIIa procoagulant, antithrombotic interventions
Abstract: It is widely accepted that blood coagulation in vivo is initiated during normal hemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor, is exposed to the blood as a consequence of vascular injury. In addition to its essential role in hemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons, the tissue factor:factor VIIa complex has been the subject of intense research focus. Many experimental studies have demonstrated that inhibition of tissue factor:factor VIIa procoagulant activity are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared to other “more classical” antithrombotic interventions. Alternative approaches may be represented by transfecting the arterial wall with natural inhibitors of tissue factor:factor VIIa complex, such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without incurring in potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in patients.
Export Options
About this article
Cite this article as:
Golino Paolo, Forte Lavinia and Rosa De Salvatore, Inhibition of the Tissue Factor Coagulation Pathway, Current Vascular Pharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570161043385402
DOI https://dx.doi.org/10.2174/1570161043385402 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
p38 MAP Kinase Mediated Proteoglycan Synthesis as a Target for the Prevention of Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Genetic Variation and Atherosclerosis
Current Genomics Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Role of Platelet Signaling in Thrombus Stabilization: Potential Therapeutic Implications
Current Signal Transduction Therapy Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Editorial [Hot Topic (1): Update on Inflammatory Processes Governing Atherosclerotic Plaque Vulnerability and Reperfusion Injury (Guest Editors: Fabrizio Montecucco and Francois Mach)]
Current Pharmaceutical Biotechnology Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry An Insight Into Mitochondrial Dysfunction and its Implications in Neurological Diseases
Current Drug Targets Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?
Current Pharmaceutical Design A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Translational Application of In Vivo Imaging and Analysis of Atherosclerotic Plaque Vulnerability Assessment
Recent Patents on Medical Imaging Microbubble: A Potential Ultrasound Tool in Molecular Imaging
Current Pharmaceutical Biotechnology Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
Current Neuropharmacology Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Understanding Relaxin in the Female Reproductive System
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents